Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

2.85USD
15 Dec 2017
Change (% chg)

$0.05 (+1.79%)
Prev Close
$2.80
Open
$2.80
Day's High
$2.88
Day's Low
$2.80
Volume
1,150
Avg. Vol
29,094
52-wk High
$6.85
52-wk Low
$2.78

Latest Key Developments (Source: Significant Developments)

Proqr reports loss of EUR 0.42 per share​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Proqr Therapeutics Nv :Proqr announces results for the third quarter of 2017.Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​.  Full Article

ProQR Therapeutics prices public offering
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ProQR Therapeutics Nv :ProQR prices approximately $20 million underwritten public offering and concurrent registered direct offering of ordinary shares.Pricing of offering of its ordinary shares at a price to public of $3.25 per share​.  Full Article

Proqr announces proposed public offering of ordinary shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Proqr Therapeutics Nv :Proqr announces proposed public offering of ordinary shares.Proqr - To use proceeds from both offerings to fund clinical trials, ongoing research & development activities​.  Full Article

ProQR doses first LCA 10 patient in clinical trial of QR-110
Monday, 13 Nov 2017 

Nov 13 (Reuters) - ProQR Therapeutics NV :ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness.ProQR Therapeutics - ‍interim safety and efficacy trial results for QR-110​ from majority of patients after 6 months of treatment are expected in 2018.ProQR Therapeutics - full 12 month treatment data for QR-110 from all patients are expected in 2019​.  Full Article

JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Proqr Therapeutics Nv :JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing‍​.  Full Article

ProQR Therapeutics posts Q2 loss per share of 0.43 euros
Wednesday, 17 Aug 2016 

ProQR Therapeutics NV : Proqr announces results for the second quarter of 2016 .Q2 loss per share eur 0.43.  Full Article

ProQR reports Q1 loss per share of EUR 0.44
Wednesday, 18 May 2016 

Proqr Therapeutics Nv : Q1 loss per share eur 0.44 .Proqr announces results for the first quarter of 2016.  Full Article

BRIEF-ProQR Receives Orphan Drug Designation From EMA For Drug Candidate Qr-313 For Dystrophic Epidermolysis Bullosa

* PROQR RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR DRUG CANDIDATE QR-313 FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage: